根据协议约定，百奥泰于近日收到由吉瑞医药一次性支付的 250 万美元里程 碑付款（实际到账金额须扣除银行手续费）。该笔款项的到账，进一步充盈了公 司的现金储备，也为公司后续管线研发和国际化战略的推进提供助力。 截至本公告披露日，BAT2206（乌司奴单抗）注射液已获美国食品药品监 督管理局（FDA）和欧洲药品管理局（EMA）批准上市，美国注册商品名 为 STARJEMZA®，欧洲注册商品名为 Usymro ®；已向国家药品监督管理局 （NMPA）提交上市申请，目前正在评审中。 协议履行的风险详见公司于 2024 年 10 月 9 日披露的《百奥泰生物制药股份 有限公司关于与 Gedeon Richter Plc.（吉瑞医药）就 BAT2206（乌司奴单抗）注 射液签署授权许可及生产、供货和商业化协议的公告》（公告编号：2024-051） 之"五、协议履行的风险分析"。 敬请广大投资者注意投资风险，公司将严格按照有关规定及时对本协议后续 进展情况履行信息披露义务。 证券代码：688177 证券简称：百奥泰 公告编号：2026-002 百奥泰生物制药股份有限公司 自愿披露关于与 Gedeon Richter Pl ...

Core Viewpoint - The company has approved a licensing and commercialization agreement for BAT2206, receiving a milestone payment of $2.5 million from Jireh Pharmaceuticals, which enhances its cash reserves and supports future pipeline development and international strategy [1] Group 1: Financial Impact - The company received a one-time milestone payment of $2.5 million, which strengthens its cash reserves [1] - The payment is expected to assist in the advancement of the company's pipeline research and international strategy [1] Group 2: Product Development - BAT2206 injection has been approved for market by the U.S. FDA and the European Medicines Agency, with the U.S. brand name STARJEMZA® and the European brand name Usymro® [1] - The company has submitted a marketing application to the National Medical Products Administration, which is currently under review [1]

Core Insights - Approximately 130 A-share companies have disclosed their performance forecasts for 2025, with around 70 companies expecting positive results, including profit increases and turnaround from losses [2][4]. Company Performance Highlights - **Zhongke Lanyun**: Expected net profit of 1.4 billion to 1.43 billion yuan, a year-on-year increase of 366.51% to 376.51%, driven by strategic investments in high-growth areas like GPU and advanced packaging [4][5]. - **Chuanhua Zhili**: Forecasted net profit of 540 million to 700 million yuan, with a growth rate of 256.07% to 361.57%, supported by optimized marketing strategies and asset structure in logistics and chemical businesses [5]. - **Bai'ao Saitou**: Anticipated net profit of 135 million yuan, reflecting a 303.57% increase, attributed to favorable market conditions [4]. - **Kangchen Pharmaceutical**: Expected net profit of 145 million to 175 million yuan, with a growth of 243% to 315%, due to the absence of goodwill impairment losses in the reporting period [5]. - **Guangku Technology**: Projected net profit of 169 million to 182 million yuan, a growth of 152% to 172%, driven by product innovation and cost control [7]. - **Lixun Precision**: Forecasted net profit of 16.518 billion to 17.186 billion yuan, with a growth of 23.59% to 28.59%, supported by innovations in manufacturing and AI integration [6]. - **Daotong Technology**: Expected net profit of 900 million to 930 million yuan, with a growth of 40.42% to 45.10%, driven by AI-driven services [6]. - **Aibisen**: Anticipated net profit of 240 million to 290 million yuan, reflecting a growth of 105.32% to 148.09%, due to increased R&D investment [7]. - **Chaohongji**: Expected net profit of 436 million to 533 million yuan, with a growth of 125% to 175%, supported by a focus on brand optimization and digital transformation [9]. - **WuXi AppTec**: Forecasted net profit of 19.151 billion yuan, with a growth of approximately 102.65%, including gains from divesting joint ventures [9]. - **Hui Sheng Biological**: Expected net profit of 23.5 million to 27.1 million yuan, indicating a turnaround, driven by market expansion and improved production efficiency [9]. Industry Performance Insights - The electronics, semiconductor, pharmaceutical, and machinery sectors are showing strong performance among listed companies [3].

Core Viewpoint - Guangzhou's Huangpu and Tianhe districts are focusing on the biopharmaceutical sector, showcasing innovative drugs and leveraging AI technology to enhance drug development efficiency [1][2][6]. Group 1: Innovative Drug Development - The innovative drug AR882 by Yipin Hong Pharmaceutical demonstrates significant efficacy in treating gout, filling a gap in oral small molecule medications [1][2]. - By 2025, China's innovative drug BD transaction scale is expected to account for 49% of the global market, with Guangzhou enterprises becoming key players in the global innovation network [2]. - Baiyoutai has achieved overseas authorization for five products totaling $750 million, with a goal of doubling annual revenue starting in 2026 and aiming for 15 global product launches by 2030 [3]. Group 2: AI Integration in Biopharmaceuticals - AI technology is becoming a crucial driver for the biopharmaceutical industry, enhancing research and production capabilities [6][7]. - Collaborations between local hospitals and AI companies aim to streamline drug discovery processes, significantly reducing the time from basic research to clinical trials [6][7]. - The global pharmaceutical AI market is projected to grow from over $4 billion in 2025 to $25.7 billion by 2030, indicating vast potential for AI in drug development [8]. Group 3: Supportive Ecosystem and Policies - The establishment of the National University Regional Technology Transfer Center in the Guangdong-Hong Kong-Macao Greater Bay Area is accelerating the transformation of research results into practical applications [5]. - Policies such as expedited approval for innovative medical devices and R&D incentives are fostering a conducive environment for biopharmaceutical innovation [4].

Core Viewpoint - Baiotai has entered into a licensing and commercialization agreement with Hikma Pharmaceuticals USA Inc. for the exclusive commercialization rights of BAT2206 (Ustekinumab) injection in the U.S. market, receiving a milestone payment of $10 million from Hikma [1] Group 1 - Baiotai signed the agreement with Hikma on August 27, 2021, granting Hikma the rights to commercialize BAT2206 in the U.S. [1] - The milestone payment of $10 million has been received by Baiotai from Hikma [1] - BAT2206 has been approved for marketing by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), with the U.S. brand name being STARJEMZA® and the European brand name Usymro® [1] Group 2 - Baiotai has submitted a marketing application to the National Medical Products Administration (NMPA) in China, which is currently under review [1]

Group 1 - China Shipbuilding Defense expects a net profit of 940 million to 1.12 billion yuan for 2025, an increase of 149.61% to 196.88% year-on-year [1] - China First Heavy Industries has only undertaken a small number of related accessory projects and has not generated revenue from them [2] - Huanyu Electronics plans to invest 30 million yuan in a private equity fund focused on AI and emerging industries [3] Group 2 - Zhixiang Jintai's GR1803 injection has been included in the priority review list by the National Medical Products Administration [4] - JianKai Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [5] - Debon Holdings will continue to suspend trading from January 12 due to significant matters being planned [6] Group 3 - South Network Technology's shareholder intends to transfer 847.05 million shares, accounting for 1.50% of the total share capital [7] - Hengrui Medicine has received approval for clinical trials of four drugs [8] - Daotong Technology expects a net profit of 900 million to 930 million yuan for 2025, a year-on-year increase of 40.42% to 45.10% [10] Group 4 - Betta Pharmaceuticals has invested 50 million yuan to acquire a 20% stake in Hangzhou Zhixing Pharmaceutical [11] - Tianyu Biology reported a 10.38% year-on-year decline in cumulative sales revenue for 2025 [12] - Lifang Pharmaceutical's subsidiary has obtained a drug registration certificate for a pain relief product [13] Group 5 - R&F Properties reported a total sales revenue of approximately 14.21 billion yuan for 2025 [14] - Wanfu Biology expects a net profit decline of 87.71% to 91.81% for 2025 [15] - Dazhi expects a negative net profit for 2025 [16] Group 6 - Dongzhu Ecology is negotiating to terminate the acquisition of control over a satellite communication company [17] - Baotai has received a milestone payment of 10 million USD from Hikma Pharmaceuticals [18] - Huace Navigation expects a net profit of 670 million to 690 million yuan for 2025, a year-on-year increase of 14.84% to 18.27% [19] Group 7 - Shenzhen Gas reported a net profit decline of 3.45% for 2025 [20] - Baogang Co. plans to adjust the price of rare earth concentrate for Q1 2026 to 26,834 yuan per ton [21] - Jiuding Investment expects to report a loss for 2025 [22] Group 8 - Shanghai Pharmaceuticals has received a drug registration certificate for a treatment for myasthenia gravis [23] - Hualan Biological plans to acquire a 35% stake in Guangfeng Capsule [24] - Ruina Intelligent plans to invest 169.9 million yuan in a new R&D production base for heat pumps [25] Group 9 - Wantong Development expects to report a loss for 2025 [26] - Xianghe Industrial has completed the purchase of a 5% stake in Hezhixiang Technology [27] - Guangkang Biochemical received a warning letter from the Guangdong Securities Regulatory Commission [28] Group 10 - Xiaoming Co. reported a 37.07% year-on-year decline in chicken product sales revenue for December 2025 [29] - Luokai Co. won a procurement project from State Grid Fujian Power worth approximately 48.2 million yuan [30] - Minhe Co. reported a 65.22% year-on-year increase in the sales of commodity chick seedlings for December 2025 [31] Group 11 - Zhenghai Biological has obtained a registration certificate for calcium silicate bio-ceramic materials [32] - Three Gorges Energy reported a 5.99% year-on-year increase in cumulative total power generation for 2025 [33] - Huisheng Biological expects a net profit of 235 million to 271 million yuan for 2025 [34] Group 12 - Maihe Co. announced the release of the detention measures against its chairman [35] - Wandong's Alzheimer's project has been included in a national major special project for innovative drug development [36] - Kangxin New Materials plans to transfer forest land assets with a book value of 1.203 billion yuan [37] Group 13 - Greenland Holdings expects a net loss of 16 billion to 19 billion yuan for 2025 [39] - Zhongxin Fluorine Materials has obtained a pesticide production license [40]

Core Viewpoint - The company received a milestone payment of $10 million from Hikma, which enhances its cash reserves and supports future pipeline development and international strategy [1] Group 1: Financial Impact - The $10 million payment will be credited after deducting bank fees, contributing positively to the company's financial position [1] Group 2: Product Development - The company's product BAT2206 (Ustinumab injection) has received approvals from both the FDA and EMA, with the U.S. brand name being STARJEMZA® and the European brand name Usymro® [1] - A marketing application for BAT2206 has been submitted to the National Medical Products Administration (NMPA) and is currently under review [1]

Core Viewpoint - The company received a milestone payment of $10 million from Hikma, which enhances its cash reserves and supports future pipeline development and international strategy [1] Group 1: Financial Impact - The $10 million payment will be credited after deducting bank fees, contributing positively to the company's financial position [1] Group 2: Product Development - The company's product BAT2206 (Ustinumab injection) has received approvals from both the FDA and EMA, with the U.S. brand name being STARJEMZA® and the European brand name Usymro® [1] - A marketing application for BAT2206 has been submitted to the National Medical Products Administration (NMPA) and is currently under review [1]

证券代码：688177 证券简称：百奥泰 公告编号：2026-001 百奥泰生物制药股份有限公司 自愿披露关于与 Hikma Pharmaceuticals USA Inc.就 BAT2206（乌司奴单抗）注射液签署授权许可与商业 化协议收到里程碑付款的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 百奥泰生物制药股份有限公司（以下简称"百奥泰"或"公司"）于 2021 年 8 月 27 日召开公司第一届董事会第二十六次会议，审议通过了《关于公司与 Hikma Pharmaceuticals USA Inc.就 BAT2206（乌司奴单抗）注射液签署许可与 商业化协议的议案》，本次签署授权协议事项不属于关联交易和重大资产重组事 项，根据《上海证券交易所科创板股票上市规则》及公司章程等相关规定，本 议案无需提交股东大会审议。公司于同日与 Hikma Pharmaceuticals USA Inc. （以下简称"Hikma"）签署授权许可与商业化协议，将公司的 BAT2206（乌司 奴单抗）注射液在美国市场的独占的产品商 ...

Core Viewpoint - The company has signed a licensing and commercialization agreement with Hikma Pharmaceuticals USA Inc. for the exclusive commercialization rights of BAT2206 (Ustekinumab) injection in the U.S. market, receiving a milestone payment of $10 million [1] Group 1 - The milestone payment received from Hikma will enhance the company's cash reserves, supporting future pipeline research and international strategic initiatives [1] - BAT2206 injection has been approved for market launch by both the U.S. FDA and the European EMA, with a submission for market approval currently under review by the National Medical Products Administration [1]